Default company panoramic image

Remedy Pharmaceuticals, Inc.

Remedy Pharmaceuticals has a breakthrough drug for stroke and TBI. The Co. has approximately $2MM in investor commitments to this round.

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location United States
  • Currency USD
  • Founded January 2005
  • Employees 2
  • Website

Company Summary

Remedy Pharmaceuticals’ drug, RP-1127, mitigates the damaging after-effects of stroke and traumatic brain injury (TBI). The US & EU market for these indications is estimated at over $4Billion. Many previous attempts to treat stroke and TBI focused on neurons and required the molecule to cross what is called the “Blood Brain Barrier”—and all failed. Remedy’s drug works in a completely different manner— on the capillaries that comprise the


  • Default avatar
    Sven Jacobson

    Experienced early stage biotech entrepreneur and investor.
    Co-founded (as CEO or COO) Remedy Pharmaceuticals, Cure Therapeutics, Critical Diagnostics, Access Scientific, St. Camillus Medical.

  • Default avatar
    Dr. Eugene Means
    Medical Director

    Group Director of CNS at Upjohn and Executive Director of CNS and Medical Leader of Emerging Products at Astra Merck / AstraZeneca.
    Worked on Tirilizad, Zendra, NXY-059.

  • Default avatar
    Dr. Marc Simard
    Founder & Chief Scientific Advisor

    Discoverer of the SUR1/TRPM4 channel.
    Professor of Neurosurgery, Pathology and Physiology, University of Maryland. Chief of Neurological Service, Baltimore V.A. Medical Center.

Previous Investors

  • Default avatar
    Carrot Capital: $4MM
    Default avatar
    ING LLC (Neurosurgeaons): >$700K
    Default avatar
    Dr. Simard: $1MM